Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant Staphylococcus aureus.

Tharmalingam N, Khader R, Fuchs BB, Mylonakis E.

Front Microbiol. 2019 Jul 17;10:1557. doi: 10.3389/fmicb.2019.01557. eCollection 2019.

2.

A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus.

Kim W, Zou G, Hari TPA, Wilt IK, Zhu W, Galle N, Faizi HA, Hendricks GL, Tori K, Pan W, Huang X, Steele AD, Csatary EE, Dekarske MM, Rosen JL, Ribeiro NQ, Lee K, Port J, Fuchs BB, Vlahovska PM, Wuest WM, Gao H, Ausubel FM, Mylonakis E.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. doi: 10.1073/pnas.1904700116. Epub 2019 Jul 29.

PMID:
31358625
3.

Auranofin is an effective agent against clinical isolates of Staphylococcus aureus.

Tharmalingam N, Ribeiro NQ, da Silva DL, Naik MT, Cruz LI, Kim W, Shen S, Dos Santos JD, Ezikovich K, D'Agata EM, Mylonakis E, Fuchs BB.

Future Med Chem. 2019 Jun;11(12):1417-1425. doi: 10.4155/fmc-2018-0544. Epub 2019 Jul 12.

PMID:
31298580
4.

Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings.

Liu H, Shukla S, Vera-González N, Tharmalingam N, Mylonakis E, Fuchs BB, Shukla A.

Front Cell Infect Microbiol. 2019 Feb 28;9:37. doi: 10.3389/fcimb.2019.00037. eCollection 2019.

5.

Rapid Isolation and Concentration of Pathogenic Fungi Using Inertial Focusing on a Chip-Based Platform.

Fuchs BB, Eatemadpour S, Martel-Foley JM, Stott S, Toner M, Mylonakis E.

Front Cell Infect Microbiol. 2019 Feb 12;9:27. doi: 10.3389/fcimb.2019.00027. eCollection 2019.

6.

Anti-Candida albicans Activity of Thiazolylhydrazone Derivatives in Invertebrate and Murine Models.

Cruz LIB, Lopes LFF, de Camargo Ribeiro F, de Sá NP, Lino CI, Tharmalingam N, de Oliveira RB, Rosa CA, Mylonakis E, Fuchs BB, Johann S.

J Fungi (Basel). 2018 Dec 12;4(4). pii: E134. doi: 10.3390/jof4040134.

7.

Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions.

Fuchs BB, Tharmalingam N, Mylonakis E.

Future Microbiol. 2018 Oct;13:1537-1547. doi: 10.2217/fmb-2018-0157. Epub 2018 Oct 12. Review.

PMID:
30311778
8.

Galleria mellonella experimental model for bat fungal pathogen Pseudogymnoascus destructans and human fungal pathogen Pseudogymnoascus pannorum.

Fuchs BB, Chaturvedi S, Rossoni RD, de Barros PP, Torres-Velez F, Mylonakis E, Chaturvedi V.

Virulence. 2018;9(1):1539-1547. doi: 10.1080/21505594.2018.1518087.

9.

Discovery and Optimization of nTZDpa as an Antibiotic Effective Against Bacterial Persisters.

Kim W, Steele AD, Zhu W, Csatary EE, Fricke N, Dekarske MM, Jayamani E, Pan W, Kwon B, Sinitsa IF, Rosen JL, Conery AL, Fuchs BB, Vlahovska PM, Ausubel FM, Gao H, Wuest WM, Mylonakis E.

ACS Infect Dis. 2018 Nov 9;4(11):1540-1545. doi: 10.1021/acsinfecdis.8b00161. Epub 2018 Aug 28.

PMID:
30132650
10.

SDH2 is involved in proper hypha formation and virulence in Candida albicans.

Bi S, Lv QZ, Wang TT, Fuchs BB, Hu DD, Anastassopoulou CG, Desalermos A, Muhammed M, Wu CL, Jiang YY, Mylonakis E, Wang Y.

Future Microbiol. 2018 Aug;13:1141-1156. doi: 10.2217/fmb-2018-0033. Epub 2018 Aug 16.

11.

Pathogenesis of the Candida parapsilosis Complex in the Model Host Caenorhabditis elegans.

Souza ACR, Fuchs BB, Alves VS, Jayamani E, Colombo AL, Mylonakis E.

Genes (Basel). 2018 Aug 8;9(8). pii: E401. doi: 10.3390/genes9080401.

12.

A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis & candidiasis in animal models.

Sá NP, Lima CM, A Dos Santos JR, Costa MC, de Barros PP, Junqueira JC, Vaz JA, Oliveira RB, Fuchs BB, Mylonakis E, Rosa CA, Santos DA, Johann S.

Future Sci OA. 2018 Apr 25;4(6):FSO305. doi: 10.4155/fsoa-2018-0001. eCollection 2018 Jul.

13.

Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities.

Porras AMG, Terra BS, Braga TC, Magalhães TFF, Martins CVB, da Silva DL, Baltazar LM, Gouveia LF, de Freitas GJC, Santos DA, Resende-Stoianoff MA, Fuchs BB, Mylonakis E, de Freitas RP, de Fátima Â.

J Adv Res. 2018 Jun 21;14:81-91. doi: 10.1016/j.jare.2018.06.004. eCollection 2018 Nov.

14.

Antifungal activity directed toward the Cell wall by 2-cyclohexylidenhydrazo-4-phenyl-thiazole against Candida albicans.

de Sa NP, Possa AP, Perez P, Ferreira JMS, Fonseca NC, Lino CI, Cruz LB, de Oliveira RB, Rosa CA, Borelli BM, Mylonakis E, Fuchs BB, Johann S.

Infect Disord Drug Targets. 2018 May 30. doi: 10.2174/1871526518666180531101605. [Epub ahead of print]

PMID:
29852876
15.

In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.

de Sá NP, de Paula LFJ, Lopes LFF, Cruz LIB, Matos TTS, Lino CI, de Oliveira RB, de Souza-Fagundes EM, Fuchs BB, Mylonakis E, Johann S.

J Glob Antimicrob Resist. 2018 Sep;14:287-293. doi: 10.1016/j.jgar.2018.04.012. Epub 2018 Apr 30.

PMID:
29715565
16.

A new class of synthetic retinoid antibiotics effective against bacterial persisters.

Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, Fuchs BB, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, Mylonakis E.

Nature. 2018 Apr 5;556(7699):103-107. doi: 10.1038/nature26157. Epub 2018 Mar 28.

17.

Strategies against methicillin-resistant Staphylococcus aureus persisters.

Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E.

Future Med Chem. 2018 Apr 1;10(7):779-794. doi: 10.4155/fmc-2017-0199. Epub 2018 Mar 23. Review.

18.

Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.

Tharmalingam N, Rajmuthiah R, Kim W, Fuchs BB, Jeyamani E, Kelso MJ, Mylonakis E.

Microb Drug Resist. 2018 Jun;24(5):666-674. doi: 10.1089/mdr.2017.0250. Epub 2018 Feb 20.

19.

Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans.

de Barros PP, Scorzoni L, Ribeiro FC, Fugisaki LRO, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC, Rossoni RD.

Microb Pathog. 2018 Apr;117:80-87. doi: 10.1016/j.micpath.2018.02.019. Epub 2018 Feb 9.

PMID:
29432910
20.

Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis.

Rossoni RD, de Barros PP, de Alvarenga JA, Ribeiro FC, Velloso MDS, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC.

Biofouling. 2018 Feb;34(2):212-225. doi: 10.1080/08927014.2018.1425402. Epub 2018 Jan 30.

PMID:
29380647
21.

Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus.

Zheng Z, Liu Q, Kim W, Tharmalingam N, Fuchs BB, Mylonakis E.

Future Med Chem. 2018 Feb;10(3):283-296. doi: 10.4155/fmc-2017-0159. Epub 2018 Jan 15.

22.

Histone acetyltransferase encoded by NGG1 is required for morphological conversion and virulence of Candida albicans.

Li DD, Fuchs BB, Wang Y, Huang XW, Hu DD, Sun Y, Chai D, Jiang YY, Mylonakis E.

Future Microbiol. 2017 Dec;12:1497-1510. doi: 10.2217/fmb-2017-0084. Epub 2017 Nov 7.

PMID:
29110536
23.

The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization.

Cabral DJ, Wurster JI, Flokas ME, Alevizakos M, Zabat M, Korry BJ, Rowan AD, Sano WH, Andreatos N, Ducharme RB, Chan PA, Mylonakis E, Fuchs BB, Belenky P.

Sci Rep. 2017 Sep 8;7(1):11040. doi: 10.1038/s41598-017-11427-2.

24.

Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus.

Tharmalingam N, Jayamani E, Rajamuthiah R, Castillo D, Fuchs BB, Kelso MJ, Mylonakis E.

Future Med Chem. 2017 Aug;9(12):1401-1411. doi: 10.4155/fmc-2017-0047. Epub 2017 Aug 3.

25.

Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.

Sá NP, Lima CM, Lino CI, Barbeira PJS, Baltazar LM, Santos DA, Oliveira RB, Mylonakis E, Fuchs BB, Johann S.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e02700-16. doi: 10.1128/AAC.02700-16. Print 2017 Aug.

26.

Synergistic Efficacy of Aedes aegypti Antimicrobial Peptide Cecropin A2 and Tetracycline against Pseudomonas aeruginosa.

Zheng Z, Tharmalingam N, Liu Q, Jayamani E, Kim W, Fuchs BB, Zhang R, Vilcinskas A, Mylonakis E.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00686-17. doi: 10.1128/AAC.00686-17. Print 2017 Jul.

27.

Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections.

Gwisai T, Hollingsworth NR, Cowles S, Tharmalingam N, Mylonakis E, Fuchs BB, Shukla A.

Biomed Mater. 2017 Jul 12;12(4):045010. doi: 10.1088/1748-605X/aa7105.

28.

Lactobacillus paracasei modulates the immune system of Galleria mellonella and protects against Candida albicans infection.

Rossoni RD, Fuchs BB, de Barros PP, Velloso MD, Jorge AO, Junqueira JC, Mylonakis E.

PLoS One. 2017 Mar 7;12(3):e0173332. doi: 10.1371/journal.pone.0173332. eCollection 2017.

29.

NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption.

Kim W, Fricke N, Conery AL, Fuchs BB, Rajamuthiah R, Jayamani E, Vlahovska PM, Ausubel FM, Mylonakis E.

Future Med Chem. 2016;8(3):257-69. doi: 10.4155/fmc.15.189. Epub 2016 Feb 24.

30.

Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin.

Fuchs BB, RajaMuthiah R, Souza AC, Eatemadpour S, Rossoni RD, Santos DA, Junqueira JC, Rice LB, Mylonakis E.

Future Med Chem. 2016;8(2):117-32. doi: 10.4155/fmc.15.182. Epub 2016 Jan 25.

31.

Erratum to: Micafungin Elicits an Immunomodulatory Effect in Galleria mellonella and Mice.

Fuchs BB, Li Y, Li D, Johnston T, Hendricks G, Li G, Rajamuthiah R, Mylonakis E.

Mycopathologia. 2016 Feb;181(1-2):27. doi: 10.1007/s11046-015-9959-1. No abstract available.

32.

Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.

Rajamuthiah R, Jayamani E, Majed H, Conery AL, Kim W, Kwon B, Fuchs BB, Kelso MJ, Ausubel FM, Mylonakis E.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5203-7. doi: 10.1016/j.bmcl.2015.09.066. Epub 2015 Sep 30.

33.

Micafungin Elicits an Immunomodulatory Effect in Galleria mellonella and Mice.

Fuchs BB, Li Y, Li D, Johnston T, Hendricks G, Li G, Rajamuthiah R, Mylonakis E.

Mycopathologia. 2016 Feb;181(1-2):17-25. doi: 10.1007/s11046-015-9940-z. Epub 2015 Sep 18. Erratum in: Mycopathologia. 2016 Feb;181(1-2):27.

34.

Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Souza AC, Fuchs BB, Pinhati HM, Siqueira RA, Hagen F, Meis JF, Mylonakis E, Colombo AL.

Antimicrob Agents Chemother. 2015 Oct;59(10):6581-7. doi: 10.1128/AAC.01177-15. Epub 2015 Aug 10.

35.

Competitive Interactions between C. albicans, C. glabrata and C. krusei during Biofilm Formation and Development of Experimental Candidiasis.

Rossoni RD, Barbosa JO, Vilela SF, dos Santos JD, de Barros PP, Prata MC, Anbinder AL, Fuchs BB, Jorge AO, Mylonakis E, Junqueira JC.

PLoS One. 2015 Jul 6;10(7):e0131700. doi: 10.1371/journal.pone.0131700. eCollection 2015.

36.

A Defensin from the Model Beetle Tribolium castaneum Acts Synergistically with Telavancin and Daptomycin against Multidrug Resistant Staphylococcus aureus.

Rajamuthiah R, Jayamani E, Conery AL, Fuchs BB, Kim W, Johnston T, Vilcinskas A, Ausubel FM, Mylonakis E.

PLoS One. 2015 Jun 10;10(6):e0128576. doi: 10.1371/journal.pone.0128576. eCollection 2015.

37.

Identification of an Antimicrobial Agent Effective against Methicillin-Resistant Staphylococcus aureus Persisters Using a Fluorescence-Based Screening Strategy.

Kim W, Conery AL, Rajamuthiah R, Fuchs BB, Ausubel FM, Mylonakis E.

PLoS One. 2015 Jun 3;10(6):e0127640. doi: 10.1371/journal.pone.0127640. eCollection 2015.

38.

Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.

Rajamuthiah R, Fuchs BB, Conery AL, Kim W, Jayamani E, Kwon B, Ausubel FM, Mylonakis E.

PLoS One. 2015 Apr 21;10(4):e0124595. doi: 10.1371/journal.pone.0124595. eCollection 2015.

39.

Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model.

Jayamani E, Rajamuthiah R, Larkins-Ford J, Fuchs BB, Conery AL, Vilcinskas A, Ausubel FM, Mylonakis E.

Antimicrob Agents Chemother. 2015 Mar;59(3):1728-37. doi: 10.1128/AAC.04198-14. Epub 2015 Jan 12.

40.

A multi-host approach for the systematic analysis of virulence factors in Cryptococcus neoformans.

Desalermos A, Tan X, Rajamuthiah R, Arvanitis M, Wang Y, Li D, Kourkoumpetis TK, Fuchs BB, Mylonakis E.

J Infect Dis. 2015 Jan 15;211(2):298-305. doi: 10.1093/infdis/jiu441. Epub 2014 Aug 11.

41.

Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E.

Clin Microbiol Rev. 2014 Jul;27(3):490-526. doi: 10.1128/CMR.00091-13. Review.

42.

The role of Candida albicans SPT20 in filamentation, biofilm formation and pathogenesis.

Tan X, Fuchs BB, Wang Y, Chen W, Yuen GJ, Chen RB, Jayamani E, Anastassopoulou C, Pukkila-Worley R, Coleman JJ, Mylonakis E.

PLoS One. 2014 Apr 14;9(4):e94468. doi: 10.1371/journal.pone.0094468. eCollection 2014.

43.

Nonmammalian model systems to investigate fungal biofilms.

Arvanitis M, Fuchs BB, Mylonakis E.

Methods Mol Biol. 2014;1147:159-72. doi: 10.1007/978-1-4939-0467-9_11.

PMID:
24664832
44.

Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus.

Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, Conery A, Ausubel FM, Mylonakis E.

PLoS One. 2014 Feb 19;9(2):e89189. doi: 10.1371/journal.pone.0089189. eCollection 2014.

45.

Correlation between Candida albicans biofilm formation and invasion of the invertebrate host Galleria mellonella.

Borghi E, Romagnoli S, Fuchs BB, Cirasola D, Perdoni F, Tosi D, Braidotti P, Bulfamante G, Morace G, Mylonakis E.

Future Microbiol. 2014;9(2):163-73. doi: 10.2217/fmb.13.159.

PMID:
24571071
46.

Selective photoinactivation of Candida albicans in the non-vertebrate host infection model Galleria mellonella.

Chibebe Junior J, Sabino CP, Tan X, Junqueira JC, Wang Y, Fuchs BB, Jorge AO, Tegos GP, Hamblin MR, Mylonakis E.

BMC Microbiol. 2013 Oct 1;13:217. doi: 10.1186/1471-2180-13-217.

47.

Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model.

Chibebe Junior J, Fuchs BB, Sabino CP, Junqueira JC, Jorge AO, Ribeiro MS, Gilmore MS, Rice LB, Tegos GP, Hamblin MR, Mylonakis E.

PLoS One. 2013;8(2):e55926. doi: 10.1371/journal.pone.0055926. Epub 2013 Feb 14.

48.

Effect of virulence factors on the photodynamic inactivation of Cryptococcus neoformans.

Prates RA, Fuchs BB, Mizuno K, Naqvi Q, Kato IT, Ribeiro MS, Mylonakis E, Tegos GP, Hamblin MR.

PLoS One. 2013;8(1):e54387. doi: 10.1371/journal.pone.0054387. Epub 2013 Jan 18.

49.

Antimicrobial photodynamic inactivation inhibits Candida albicans virulence factors and reduces in vivo pathogenicity.

Kato IT, Prates RA, Sabino CP, Fuchs BB, Tegos GP, Mylonakis E, Hamblin MR, Ribeiro MS.

Antimicrob Agents Chemother. 2013 Jan;57(1):445-51. doi: 10.1128/AAC.01451-12. Epub 2012 Nov 5.

50.

Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform.

Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St Denis TG, Ribeiro MS, Mylonakis E, Hamblin MR, Tegos GP.

Front Microbiol. 2012 Apr 10;3:120. doi: 10.3389/fmicb.2012.00120. eCollection 2012.

Supplemental Content

Loading ...
Support Center